Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
Niels Willem Boone, Roelof Wouter Frederik van LeeuwenMaastricht University Medical Centre, Department of Clinical Pharmacy and Toxicology, Maastricht, The NetherlandsRecently our hospital pharmacy, which serves an academic hospital with an internationally well-known department of ophthalmology, rec...
Guardado en:
Autores principales: | Boone NW, van Leeuwen RWF |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/43edcb1ca8cf4cafa08fd527b225072a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration
por: Luis Arias, et al.
Publicado: (2010) -
Displacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumab
por: Sukhpal Singh Sandhu, et al.
Publicado: (2010) -
An origami paper-based nanoformulated immunosensor detects picograms of VEGF-C per milliliter of blood
por: Shuai Sun, et al.
Publicado: (2021) -
Case–control diagnostic accuracy study of a non-sputum CD38-based TAM-TB test from a single milliliter of blood
por: Hellen Hiza, et al.
Publicado: (2021) -
Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA.
por: Mitsunori Ishiguro, et al.
Publicado: (2010)